Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023
Mineralys Therapeutics (NASDAQ: MLYS) announced its plan to release financial results for the fourth quarter ending December 31, 2022, on March 15, 2023, post-market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mineralys Therapeutics (NASDAQ: MLYS) announced its plan to release financial results for the fourth quarter ending December 31, 2022, on March 15, 2023, post-market close. A conference call with management is scheduled for 4:30 p.m. ET on the same day, accessible via 1-877-704-4453 (U.S.) or 1-201-389-0920 (international) with conference ID 13736564. The company is focused on developing treatments for diseases linked to high aldosterone levels, with its lead candidate, lorundrostat, targeting uncontrolled hypertension.
Details
News Market Reaction – MLYS
The recorded move for MLYS in the trading session of this news was -3.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter ended December 31, 2022, after the financial markets close on Wednesday, March 15, 2023.
The Company’s management team will host a conference call at 4:30 p.m. ET on Wednesday, March 15, 2023. To access the call, please dial 1-877-704-4453 in the U.S. or 1-201-389-0920 outside the U.S., followed by the conference ID: 13736564. A live webcast of the conference call may be found here. A replay of the call will be available on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
| Wednesday, March 15 @ 4:30 p.m. ET | ||
| Domestic: | 1-877-704-4453 | |
| International: | 1-201-389-0920 | |
| Conference ID: | 13736564 | |
| Webcast: | Link | |
About Mineralys
Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its primary product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension.
Mineralys is based in Radnor, Pennsylvania. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn.
Contact:
investorrelations@mineralystx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.